Revolution-Adjuvant Daraxonrasib vs SOC in resected PDAC (RASolute 304) - Clinical Trial

¿Quién puede participar en el Estudio?

Grupo etario

Adultos

Detalles del Estudio

Título Completo

[RMC-6236-304] RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Investigador Principal